AbbVie’s tavapadon has demonstrated positive results as a monotherapy for early Parkinson’s disease, according to a Sept. 26 news release from the drugmaker.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
AbbVie drug shows promise in treating Parkinson's: 3 notes
